{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:30:54Z","timestamp":1790965854135,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":884,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1124\/dmd.122.000829","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T20:40:11Z","timestamp":1655239211000},"page":"1106-1118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans"],"prefix":"10.1016","volume":"50","author":[{"given":"Jonathan N.","family":"Bauman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"King-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Telliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakambari","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theunis C.","family":"Goosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-6388","authenticated-orcid":false,"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.000829_bib1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Akada","year":"2014","journal-title":"Stem Cells"},{"key":"10.1124\/dmd.122.000829_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.000829_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.122.000829_bib4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1124\/dmd.122.000829_bib5721944","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000829_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/tx800432c","article-title":"Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development","volume":"22","author":"Leclercq","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.000829_bib6","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/bcp.13612","article-title":"Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study","volume":"84","author":"Peeva","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000829_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.116.074575","article-title":"Novel method to predict in vivo liver-to-plasma Kpuu for OATP substrates using suspension hepatocytes","volume":"45","author":"Riccardi","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000829_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1124\/dmd.122.000829_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000829_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/psp4.12540","article-title":"Mini-review: comprehensive drug disposition knowledge generated in the modern human radiolabeled ADME study","volume":"9","author":"Spracklin","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.000829_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1124\/dmd.122.000829_bib12","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.1021\/ac5015035","article-title":"Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range","volume":"86","author":"van Duijn","year":"2014","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.122.000829_bib13","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1124\/dmd.107.015883","article-title":"A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1\u2032,1\u2032'-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6","volume":"35","author":"Walsky","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000829_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jcph.1858","article-title":"Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"61","author":"Wang","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000829_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1980","article-title":"Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites","volume":"62","author":"Wang","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000829_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","article-title":"Assessment of the effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals","volume":"47","author":"Wang","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.000829_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.000829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:01:44Z","timestamp":1740765704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624008468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0090955624008468"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.000829","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.000829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}